HilleVax, Inc.
HLVXDelisted Sep 17, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001888012
HilleVax, Inc. was delisted on Sep 17, 2025; its insiders filed their last Form 4 on Sep 19, 2025; 74 institutions reported holding it in 13F filings for Q2 2025, worth $82.5M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by HilleVax, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for HilleVax, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | 10% Owner | 0Indirect | Sep 19, 2025 | 0 |
| Takeda Vaccines, Inc. | 10% Owner | 0Indirect | Sep 19, 2025 | 0 |
| Topper James N | 10% Owner | 0Indirect | Sep 17, 2025 | 0 |
| Heron Patrick J | Director, 10% Owner | 0Indirect | Sep 17, 2025 | 0 |
| FHMLS X, L.L.C. | 10% Owner | 0Indirect | Sep 17, 2025 | 0 |
| Frazier Life Sciences X, L.P. | 10% Owner | 0Indirect | Sep 17, 2025 | 0 |
| FHMLS X, L.P. | 10% Owner | 0Indirect | Sep 17, 2025 | 0 |
| Hilleman Jeryl L | Director | 0 | Sep 17, 2025 | 0 |
| Hershberg Robert | President and CEO | 0 | Sep 17, 2025 | 0 |
| Gerberding Julie L. | Director | 0 | Sep 17, 2025 | 0 |
| Maltbie Shane | Chief Financial Officer | 0 | Sep 17, 2025 | 0 |
| Kohli Aditya | Director | 0 | Sep 17, 2025 | 0 |
| Chu Shelley | Director | 0 | Sep 17, 2025 | 0 |
| Sepulveda Jaime | Director | 0 | Sep 17, 2025 | 0 |
| Dubin Gary | Director | 0 | Sep 17, 2025 | 0 |
| Cocero Nanette | Director | 0 | Sep 17, 2025 | 0 |
| McLoughlin Sean | Chief Operating Officer | 1,250 | Apr 1, 2024 | 0 |
| Borkowski Astrid | Chief Medical Officer | 214,892 | Feb 12, 2024 | 0 |
| Silbermann Susan Michele | Director | – | Aug 23, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2025 (view filing) | Feb 4-11 | 8 daysLate | Hershberg RobertSee Remarks | SSale | −26.5K | $1.83 | −$48.6K | −2.4%1.10M after | 2 lots |
| Feb 12, 2025 (view filing) | Feb 4-11 | 8 daysLate | Maltbie ShaneChief Financial Officer | SSale | −8.29K | $1.82 | −$15.1K | −9.4%79.9K after | 2 lots |
| May 22, 2024 (view filing) | May 20-22 | 2 days | Kohli AdityaDirector | SSale | −18.0K | $14.80 | −$266.3K | −2.3%764.9K after | 3 lots10b5-1 |
| May 3, 2024 (view filing) | May 1-3 | 2 days | Kohli AdityaDirector | SSale | −6.90K | $14.03 | −$96.7K | −0.9%782.9K after | 3 lots10b5-1 |
| Apr 5, 2024 (view filing) | Apr 3-5 | 2 days | Kohli AdityaDirector | SSale | −18.0K | $14.69 | −$264.5K | −2.2%789.8K after | 3 lots10b5-1 |
| Apr 1, 2024 (view filing) | Mar 28 | 4 days | McLoughlin SeanChief Operating Officer | PPurchase | +1.25K | $16.98 | +$21.2K | New position1.25K after | |
| Mar 20, 2024 (view filing) | Mar 18-20 | 2 days | Kohli AdityaDirector | SSale | −18.0K | $54,752.03 | −$985.5M | −2.2%807.8K after | 3 lots10b5-1Price outlier |
| Mar 8, 2024 (view filing) | Mar 6-8 | 2 days | Kohli AdityaDirector | SSale | −18.0K | $18.66 | −$335.9K | −2.1%825.8K after | 3 lots10b5-1 |
| Feb 22, 2024 (view filing) | Feb 20-22 | 2 days | Kohli AdityaDirector | SSale | −18.0K | $14.95 | −$269.1K | −2.1%843.8K after | 3 lots10b5-1 |
| Feb 14, 2024 (view filing) | Feb 12 | 2 days | Kohli AdityaDirector | SSale | −6.00K | $15.32 | −$91.9K | −0.7%861.8K after | 10b5-1 |
| Feb 12, 2024 (view filing) | Feb 8 | 4 days | Kohli AdityaDirector | SSale | −8.87K | $14.93 | −$132.4K | −1.1%812.9K after | |
| Feb 12, 2024 (view filing) | Feb 8 | 4 days | Maltbie ShaneChief Financial Officer | SSale | −3.58K | $14.93 | −$53.4K | −8.1%40.7K after | |
| Feb 12, 2024 (view filing) | Feb 8 | 4 days | Hershberg RobertSee Remarks | SSale | −11.6K | $14.93 | −$173.1K | −1.2%953.8K after | |
| Feb 12, 2024 (view filing) | Feb 8 | 4 days | Borkowski AstridChief Medical Officer | SSale | −3.93K | $14.93 | −$58.7K | −2.4%161.3K after | |
| Dec 18, 2023 (view filing) | Dec 15 | 3 days | Borkowski AstridChief Medical Officer | SSale | −10.0K | $15.50 | −$155.0K | −5.7%165.2K after | |
| Dec 5, 2023 (view filing) | Dec 1-4 | 4 days | Borkowski AstridChief Medical Officer | SSale | −20.0K | $14.35 | −$287.0K | −10.2%175.2K after | 2 lots |
| Nov 20, 2023 (view filing) | Nov 17 | 3 days | Borkowski AstridChief Medical Officer | SSale | −10.0K | $14.00 | −$140.0K | −4.9%195.2K after | |
| Nov 13, 2023 (view filing) | Nov 8 | 5 days | Borkowski AstridChief Medical Officer | SSale | −5.00K | $13.00 | −$65.0K | −2.4%205.2K after | |
| May 3, 2022 (view filing)4:23 PM ET | May 3 | Same day | Heron Patrick J and 4 othersDirector, 10% Owner | PPurchase | +1.76M | $17.00 | +$30.0M | +26.1%8.54M after |